SAN DIEGO, June 1, 2017 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a precision medicine biotechnology company, today announced that its Chief Executive Officer, Bill Welch, will be presenting at the Marcum 2017 MicroCap Conference on June 15, 2017 at 3:00 PM EDT at the Grand Hyatt Hotel in Julliard on the conference level. Management will also be available to meet with investors during the conference.
The presentation will be webcast live at http://wsw.com/webcast/marcum5/trov and can also be accessed through the Trovagene website at www.trovagene.investorroom.com. A replay of the presentation will be available and archived for 90 days.
About Trovagene, Inc.
Trovagene is a precision medicine biotechnology company developing oncology therapeutics for improved cancer care by leveraging its proprietary Precision Cancer Monitoring® (PCM) technology in tumor genomics. Trovagene has broad intellectual property and proprietary technology to measure circulating tumor DNA (ctDNA) in urine and blood to identify and quantify clinically actionable markers for predicting response to cancer therapies. Trovagene offers its PCM technology at its CLIA/CAP – accredited laboratory and plans to continue to vertically integrate its PCM technology with precision cancer therapeutics. For more information, please visit www.trovagene.com.
VP, Corporate Communications
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/trovagene-to-present-at-the-marcum-2017-microcap-conference-on-june-15-in-new-york-city-300467045.html
SOURCE Trovagene, Inc.